WHAT IS CLAIMED IS:

1. A powder formulation adapted for reconstitution with a diluent which comprises

a) 3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-1H-quinolin-2-one, as an active ingredient, and

b) at least one filler, wherein said filler(s) are about 10% to about 75% of the weight of the powder formulation.

2. The powder formulation of Claim 1, wherein the filler is selected from microcrystalline cellulose, lactose hydrous, Dipac, Mannitol, and a combination thereof.

3. The powder formulation of Claim 2, wherein the filler is microcrystalline cellulose, lactose hydrous or a combination thereof.

4. A powder blend formulation adapted for reconstitution with a diluent which comprises

a) 3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-1H-quinolin-2-one, as an active ingredient, and

b) at least one filler, wherein said filler(s) are about 10% of the weight of the blended formulation.

5. The powder blend formulation of Claim 4, wherein the filler is selected from microcrystalline cellulose, lactose hydrous, Dipac, Mannitol, and a combination thereof.

6. The powder blend formulation of Claim 5, wherein the filler is microcrystalline cellulose, lactose hydrous or a combination thereof.

7. A granulation formulation adapted for reconstitution with a diluent which comprises

a) 3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-1H-quinolin-2-one as an active ingredient;

b) at least one binder; and

c) at least one filler, wherein said filler(s) is about 10% to about 75% of the weight of the granulation formulation.

8. The granulation formulation of Claim 7, wherein the filler is selected from microcrystalline cellulose, lactose hydrous, Dipac, Mannitol, and a combination thereof.

9. The granulation formulation of Claim 8, wherein the filler is microcrystalline cellulose, lactose hydrous or a combination thereof.

10. The granulation formulation of Claim 7, wherein water is used in combination with a diluent for reconstitution of the granulation formulation.

11. The granulation formulation of Claim 7, wherein the granulation formulation further comprises one or more pharmaceutically acceptable excipients selected from binders, disintegrants, lubricants, flavorings, sweeteners, buffering agents, stabilizers, and viscosity modifiers.

12. A method of preparing the granulation formulation of Claim 7 which comprises:

a) preparing wet granules comprising 3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-1H-quinolin-2-one and fillers via wet granulation;

b) drying the wet granules and then milling to produce milled granules;

c) lubricating the milled granules with a lubricant to produce the granulation formulation; and

d) filling a container with the granulation formulation.

13. A kit for preparing a pharmaceutical suspension which comprises

a) granules of 3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-1H-quinolin-2-one;

b) a diluent; and

c) at least one filler.

14. The kit of Claim 13, wherein the diluent is selected from Humco's Simple Syrup, Emerson Cherry Syrup, Paddock's Ora-Sweet® Syrup, Paddock's Ora-Plus® Oral Suspending Vehicle, Ora-Sweet SF™ Sugar Free Syrup, and a combination thereof.

15. The kit of Claim 14 wherein the diluent is Humco's Simple Syrup.

16. The kit of Claim 13, wherein the filler is selected from microcrystalline cellulose, lactose hydrous, or a combination thereof.

17. An aqueous suspension formulation which comprises granules of 3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-1H-quinolin-2-one, at least one binder and at least one filler, mixed with a diluent.

18. The aqueous suspension formulation of Claim 17, wherein the diluent is selected from Humco's Simple Syrup, Emerson Cherry Syrup, Paddock's Ora-Sweet® Syrup, Paddock's Ora-Plus® Oral Suspending Vehicle, Ora-Sweet SF™ Sugar Free Syrup, and a combination thereof.

19. The powder formulation of Claim 18 wherein the diluent is Humco's Simple Syrup.

20. The aqueous suspension formulation of Claim 17 which comprises granules which comprise 3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-1H-quinolin-2-one HCl, microcrystalline cellulose, lactose hydrous, hydroxypropyl cellulose EXF and croscarmellose sodium, which are mixed with a solution of Humco Simple Syrup and water.

21. A method of preparing a pharmaceutical supsension of 3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-1H-quinolin-2-one which comprises mixing the granulation formulation of Claim 7 with a diluent.

22. The method of Claim 21, wherein the diluent is selected from Humco's Simple Syrup, Emerson Cherry Syrup, Paddock's Ora-Sweet® Syrup, Paddock's Ora-Plus® Oral Suspending Vehicle, Ora-Sweet SF™ Sugar Free Syrup, and a combination thereof.

23. The method of Claim 22 wherein the diluent is Humco's Simple Syrup.

24. The method of Claim 21 wherein the granulation formulation is mixed with a solution of Humco's Simple Syrup and water.

25. A method of treating cancer in a pediatric or adult patient comprising administering to a patient in need thereof an effective amount of the formulation of Claim 7.

26. A method of treating cancer in a pediatric or adult patient comprising administering to a patient in need thereof an effective amount of the formulation of Claim 17.